Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma - 13/01/18
Abstract |
Background |
Melasma is a common pigmentary disorder that is often difficult to treat. Tranexamic acid (TA) has emerged as a promising treatment for melasma; however, few controlled studies exist.
Objective |
To determine the efficacy of oral TA in patients with moderate-to-severe melasma.
Methods |
Patients with moderate-to-severe melasma were treated with 250 mg of TA or placebo capsules twice daily for 3 months and sunscreen followed by 3 months of treatment with sunscreen only. The primary outcome measure was the modified Melasma Area and Severity Index (mMASI) score.
Results |
A total of 44 patients were enrolled and 39 completed the study. At 3 months, there was a 49% reduction in mMASI score in the TA group versus 18% in the control group. Patients with severe melasma improved more than those with moderate melasma. Three months after treatment was stopped, there was a 26% reduction in mMASI score in the TA group compared with the baseline visit versus a 19% reduction in the placebo arm. No serious adverse events were noted in either group.
Limitations |
Single-center study enrolling predominantly Hispanic women.
Conclusions |
Oral TA appears to be an effective treatment for moderate-to-severe melasma with minimal side effects.
Le texte complet de cet article est disponible en PDF.Key words : evidence-based medicine, Hispanic, melanin, melasma, pigmentation, randomized controlled trial, tranexamic acid
Abbreviations used : HQ, MASI, mMASI, QoL, SPT, TA, UTSW
Plan
| Funding sources: None. |
|
| Conflicts of interest: None declared. |
|
| Reprints not available from the authors. |
Vol 78 - N° 2
P. 363-369 - février 2018 Retour au numéro
Article précédent
- Epidemiology of hyperhidrosis in 2 population-based health care databases
- Kristen Ricchetti-Masterson, J. Morel Symons, Molly Aldridge, Ayush Patel, Joe Maskell, John Logie, Yuji Yamaguchi, Suzanne F. Cook
- The superiorly based bilobed flap for nasal reconstruction
- Michael Kelly-Sell, S. Tyler Hollmig, Joel Cook
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?